-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Anti-BCMA CAR-T Cells in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anti-BCMA CAR-T Cells in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anti-BCMA CAR-T Cells in Refractory Multiple Myeloma Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RD-138 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RD-138 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RD-138 in Refractory Multiple Myeloma Drug Details: RD-138 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RD-138 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RD-138 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RD-138 in Relapsed Multiple Myeloma Drug Details: RD-138 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RD-138 in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RD-138 in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RD-138 in Plasma Cell Neoplasm Drug Details: RD-138 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Equecabtagene Autoleucel in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Equecabtagene Autoleucel in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Equecabtagene Autoleucel in Relapsed Multiple Myeloma Drug Details: Equecabtagene autoleucel...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Equecabtagene Autoleucel in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Equecabtagene Autoleucel in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Equecabtagene Autoleucel in Refractory Multiple Myeloma Drug Details: Equecabtagene autoleucel...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Follicular Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Follicular Lymphoma Drug Details: NKTR-255 is under development for the treatment of relapsed...
-
Product Insights
Secondary (Hypogonadotropic) Hypogonadism – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2023’, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Male Hypogonadism – Drugs In Development, 2023
Global Markets Direct’s, ‘Male Hypogonadism - Drugs In Development, 2023’, provides an overview of the Male Hypogonadism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Drugs In Development, 2023’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...